IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

IceCure Medical (Nasdaq:ICCM) announced today that it received an intention to grant notice from the European Patent Office.

IceCure Medical’s next-generation cryoablation technology to receive European patent: Caesarea, Israel Monday, January 6, 2025, 13:00 Hrs [IST] IceCure Medical Ltd., a developer ...

(UT Southwestern Medical Center) Cryoablation has not been approved by the U.S. Food and Drug Administration for breast cancer treatment, although an advisory committee for the agency did recently ...

(Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal ...

Icecure Medical ( ) has issued an update. IceCure Medical has received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic system connector t ...

IceCure Medical has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This milestone indicates the company’s stabilized ...

IceCure Medical Ltd. (NASDAQ: ICCM) watched its shares make marginal gains Friday. The Israeli-based developer of ...

Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision ...